← Russell 3000 cross-section

RNAC Cartesian Therapeutics, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$301m
Revenue TTM
$0m
Net income TTM
$-152m
Free cash flow
$-79m
Composite score
Sector rank
#2658

Valuation

P / E
EV / EBITDA
EV / sales
FCF yield
-26.10%
Earnings yield vs 10-yr
-55.16pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
EBITDA margin
ROE
121.3%
ROIC
Revenue growth

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Beginning on January 1, 2029, the Loan Agreement requires the Company to maintain compliance with a minimum trailing three -month net product revenue covenant of $ 40.0 million, tested as of the last day of each calendar quarter, with required quarter-over-quarter growth. The Company’s obligations under the Loan Agreement are secured by a first priority security interest in substantially all of the Company’s assets, excluding intellectual property, which is subject to a negative pledge. The shares of common stock sold pursuant to the Sales Agreement will be issued pursuant to the Company’s shelf registration statement on Form S-3 (File No. …Cartesian Therapeutics, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →